Trimetazidine (hydrochloride) (CAS No 13171-25-0) is a pharmacological agent primarily studied in the cardiovascular research field Originating from anti-ischemic drug development it functions by optimizing cellular metabolism under hypoxic conditions predominantly through the inhibition of long-chain 3-ketoacyl-CoA thiolase in the cardiac mitochondrial beta-oxidation pathway This action shifts fatty acid oxidation to glucose oxidation enhancing myocardial glucose consumption and efficiency during ischemic episodes Common in vitro activity occurs in the nanomolar to low micromolar range Trimetazidine is frequently used in various experimental applications including cell models like cardiomyocytes animal studies investigating myocardial protection and drug screening for cardiovascular therapies Experimental concentrations typically depend on the specific research design enabling a tailored approach to exploring its cardioprotective effects in different contexts